Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Arg Vasopressin
2. Arg-vasopressin
3. Arginine Vasopressin
4. Argipressin Tannate
5. Vasopressin, Arginine
1. Arginine Vasopressin
2. 113-79-1
3. Argipressine
4. Pitressin
5. Beta-hypophamine
6. 8-arginine-vasopressin
7. Argipressin Tannate
8. Vasopressin (arginine Form)
9. Arginine-vasopressin
10. Chebi:34543
11. Vasophysin
12. Arg-vasopressin
13. Chembl373742
14. (arg8)-vasopressin
15. [arg8]-vasopressin
16. (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
17. 8-l-arginine Vasopressin
18. Argipresina
19. Argipressina
20. Argipressinum
21. Avp
22. Arg8-vasopressin
23. Argipressin [inn]
24. Argipressina [dcit]
25. Ncgc00166306-01
26. Argipressin [inn:ban]
27. 8-l-arginine-vasopressin
28. Argipresina [inn-spanish]
29. Argipressine [inn-french]
30. Argipressinum [inn-latin]
31. Unii-y4907o6mfd
32. Rindervasopressin
33. [3h]vasopressin
34. Einecs 204-035-4
35. 3-(phenylalanine)-8-arginineoxytocin
36. Arg8-vasopressin;avp
37. Arginine-8-vasopressin
38. Argipressin Or Lypressin
39. [8-arginine]vasopressin
40. [3h]argipressin Tannate
41. Antidiuretic Hormone (adh)
42. Arginine Vasopressin (avp)
43. Argipressin Tannate [usan]
44. Arginine Antidiuretic Hormone
45. Dsstox_cid_28324
46. Dsstox_rid_82752
47. Dsstox_gsid_48349
48. Schembl43139
49. Vasopressin, 8-l-arginine-
50. [cyclo S-s]cyfqncprg-nh2
51. Gtpl2168
52. Y4907o6mfd
53. Dtxsid0048349
54. Schembl17874853
55. Bdbm35667
56. Tox21_113037
57. Bdbm50044777
58. Mfcd00076738
59. Ncgc00166306-02
60. Ncgc00188439-01
61. Cas-113-79-1
62. H-cys-tyr-phe-gln-asn-cys-pro-arg-gly-nh2
63. Oxytocin, 3-(l-phenylalanine)-8-l-arginine-
64. Vasopressin, 8-l-arginine- (7ci,8ci,9ci)
65. Roxybenzyl-6,9,12,15,18-pentaoxo- (6ci)
66. 113a791
67. Q183011
68. Cys-tyr-phe-gln-asn-cys-pro-arg-gly-nh2[disulfide Bridge: 1-6]
69. (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
70. 1,2-dithia-5,8,11,14,17-pentaazacycloeicosane-10-propionamide, 19-amino-13-benzyl-7-(carbamoylmethyl)-4-[2-[[1-[(carbamoylmethyl)carbamoyl]-4-guanidinobutyl]carbamoyl]-1-pyrrolidinylcarbonyl]-16-p-hyd
71. 1-{[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-l-prolyl-l-arginylglycinamide
72. Glycinamide, L-cysteinyl-l-tyrosyl-l-phenylalanyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-arginyl-, Cyclic (1>6)-disulfide
Molecular Weight | 1084.2 g/mol |
---|---|
Molecular Formula | C46H65N15O12S2 |
XLogP3 | -4.8 |
Hydrogen Bond Donor Count | 14 |
Hydrogen Bond Acceptor Count | 16 |
Rotatable Bond Count | 19 |
Exact Mass | 1083.43785492 g/mol |
Monoisotopic Mass | 1083.43785492 g/mol |
Topological Polar Surface Area | 515 Ų |
Heavy Atom Count | 75 |
Formal Charge | 0 |
Complexity | 2070 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Vasoconstrictor Agents
Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)
Antidiuretic Agents
Agents that reduce the excretion of URINE, most notably the octapeptide VASOPRESSINS. (See all compounds classified as Antidiuretic Agents.)
Hemostatics
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. (See all compounds classified as Hemostatics.)
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-09-29
Pay. Date : 2017-08-24
DMF Number : 28532
Submission : 2014-08-01
Status : Active
Type : II
NDC Package Code : 52416-127
Start Marketing Date : 2019-05-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-09-11
Pay. Date : 2018-08-27
DMF Number : 33119
Submission : 2018-08-27
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-07-13
Pay. Date : 2018-05-04
DMF Number : 32769
Submission : 2018-05-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25736
Submission : 2012-01-24
Status : Active
Type : II
NDC Package Code : 35207-0005
Start Marketing Date : 2012-07-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-01-19
Pay. Date : 2022-11-25
DMF Number : 37634
Submission : 2022-12-03
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-03-02
Pay. Date : 2017-10-04
DMF Number : 32116
Submission : 2017-10-03
Status : Active
Type : II
NDC Package Code : 63586-0004
Start Marketing Date : 2023-01-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-03-06
Pay. Date : 2017-11-27
DMF Number : 32146
Submission : 2017-10-12
Status : Active
Type : II
NDC Package Code : 41701-008
Start Marketing Date : 2016-03-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (0.3g/.3g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5410
Submission : 1984-04-04
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Ukraine
Brand Name : Projecta
Dosage Form : Solution for Injection
Dosage Strength : 20 VUML
Packaging : 1ML
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Ukraine
Regulatory Info :
Registration Country : Norway
Brand Name : Embesin
Dosage Form : Concentrate for infusion solution, solution
Dosage Strength : 20 IE/ml
Packaging : Ampoule av glass 10 2ml
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Arginine Vasopressin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Arginine Vasopressin, including repackagers and relabelers. The FDA regulates Arginine Vasopressin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Arginine Vasopressin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Arginine Vasopressin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Arginine Vasopressin supplier is an individual or a company that provides Arginine Vasopressin active pharmaceutical ingredient (API) or Arginine Vasopressin finished formulations upon request. The Arginine Vasopressin suppliers may include Arginine Vasopressin API manufacturers, exporters, distributors and traders.
click here to find a list of Arginine Vasopressin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Arginine Vasopressin DMF (Drug Master File) is a document detailing the whole manufacturing process of Arginine Vasopressin active pharmaceutical ingredient (API) in detail. Different forms of Arginine Vasopressin DMFs exist exist since differing nations have different regulations, such as Arginine Vasopressin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Arginine Vasopressin DMF submitted to regulatory agencies in the US is known as a USDMF. Arginine Vasopressin USDMF includes data on Arginine Vasopressin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Arginine Vasopressin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Arginine Vasopressin suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Arginine Vasopressin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Arginine Vasopressin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Arginine Vasopressin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Arginine Vasopressin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Arginine Vasopressin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Arginine Vasopressin suppliers with NDC on PharmaCompass.
Arginine Vasopressin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Arginine Vasopressin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Arginine Vasopressin GMP manufacturer or Arginine Vasopressin GMP API supplier for your needs.
A Arginine Vasopressin CoA (Certificate of Analysis) is a formal document that attests to Arginine Vasopressin's compliance with Arginine Vasopressin specifications and serves as a tool for batch-level quality control.
Arginine Vasopressin CoA mostly includes findings from lab analyses of a specific batch. For each Arginine Vasopressin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Arginine Vasopressin may be tested according to a variety of international standards, such as European Pharmacopoeia (Arginine Vasopressin EP), Arginine Vasopressin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Arginine Vasopressin USP).
LOOKING FOR A SUPPLIER?